Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study.
- Catharina M Mulders-Manders,
- Tim A Kanters,
- Paul L A van Daele,
- Esther Hoppenreijs,
- G Elizabeth Legger,
- Jan A M van Laar,
- Anna Simon,
- Leona Hakkaart-van Roijen
Orphanet J Rare Dis 2018 Apr 20;13(1):59. Epub 2018 Apr 20.
Erasmus University Rotterdam, Institute for Medical Technology Assessment, Bayle Building - Campus Woudestein, PO box 1738, 3000, DR, Rotterdam, The Netherlands.
Background: Cryopyrin-associated periodic syndrome (CAPS) is a rare disease. Knowledge on the quality of life (QoL) and the disease's societal impact is limited. Canakinumab is used in increasing frequency for the treatment of CAPS. Read More